Neuspera Medical announces milestone case of traditional sacral neuromodulation (SNM) system removed and replaced with the company’s integrated SNM system for urinary urge incontinence
Patient Struggled with SNM Battery Pain and Complications; Reports Full Complication Relief Following Implant of Neuspera’s SNM Therapy
New Patient Registry to Track Outcomes of SNM to iSNM Procedures
SAN JOSE, Calif., Feb. 10, 2026 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced a milestone patient revision from a traditional sacral neuromodulation (SNM) system to the recently FDA-approved Neuspera SNM System, an integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI).
The revision, a follow-up surgery that replaces or repairs an existing implant, was performed at University of Louisville Health (UofL Health) in Kentucky. The patient, a 21-year-old woman, experienced persistent battery discomfort and lead issues after receiving a conventional SNM implant, and a prior surgical revision with the conventional system did not improve her symptoms. After receiving the Neuspera iSNM system, the patient experienced immediate and complete complication relief, according to her surgeon. The case highlights the transformative potential of Neuspera’s technology for patients seeking UUI symptom relief without the chronic pain, surgical risks, and restrictions caused by implanted batteries.
